Project Grant R01HL179839
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $782K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $778,202 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research targeting inflammaging-induced endothelial injury and acute respiratory distress syndrome (ARDS) development in aging lungs. The research investigates how aging influences endothelial barrier injury mechanisms in ARDS, with focus on endothelial NADPH oxidase 2 (NOX2)...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Washington University $635,247 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of resolution-phase neutrophils in acute respiratory distress syndrome (ARDS) recovery. The project tests the hypothesis that neutrophils activate counter-regulatory mechanisms, including expression of 15-lipoxygenase (15-LO), in lung tissue following acute injury to...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $876,614 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multisite prospective cohort study advancing acute respiratory infection treatment in pediatric invasive home mechanical ventilation. The research will enroll 400 children in English and Spanish language families using long-term home mechanical...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $748,677 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop nanoparticle delivery systems targeting lung endothelial cell repair in pediatric acute respiratory distress syndrome (ARDS). The research addresses the lack of innovative molecular approaches to pediatric ARDS management by engineering lung endothelial cell-specific nanoparticle carriers capable of delivering...
- The National Heart Lung and Blood Institute awarded Northwestern University $654,762 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory T cell mechanisms limiting persistent inflammation during recovery from viral pneumonia. The award funds research into how FOXP3+ regulatory T cells orchestrate lung repair after viral pneumonia through expression of suppressive mediators, particularly the anti-inflammatory cytokine interleukin-10. The...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $1,541,783 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate novel roles of the thrombin receptor protease-activated receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome. The research uses mouse models to examine PAR1's role in button junction formation during lung injury. The work identifies how...
- The National Heart, Lung, and Blood Institute awarded The Feinstein Institutes for Medical Research $586,866 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the protective role of B-1a cells in acute lung injury and to evaluate a novel therapeutic compound. The project examines the mechanisms by which B-1a cells mitigate acute lung injury and acute respiratory distress syndrome, conditions frequently triggered by sepsis or ischemia-reperfusion...
- The National Heart, Lung, and Blood Institute awarded Northwestern University $1,589,058 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 25, 2026, to support research on disordered mitochondrial proteostasis and alveolar epithelial repair in aging lungs. The project investigates how age-related dysfunction in mitochondrial complex I impairs lung recovery following viral pneumonia, with a focus on the role of alveolar epithelial type 2 cells in epithelial repair and the...
- The National Heart, Lung, and Blood Institute awarded the University of Illinois $670,622 as a Project Grant (R01HL180941) on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into the role of endogenous RNA sensing in the amplification of lung injury. The research focuses on how lung infections induce widespread lung vascular endothelial injury through a cycle of endothelial barrier breakdown and inflammatory cell influx. The project...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...